http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103315947-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27b9ecde0bea3c483a646cf7655a9b2d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-183 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-65 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 |
| filingDate | 2012-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11d6ff4914b36f35357eeb89eea9c628 |
| publicationDate | 2013-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103315947-A |
| titleOfInvention | Tigecycline composition for injection |
| abstract | The present invention discloses a tigecycline composition for injection. The composition comprises active components such as tigecycline and a proppant, and further comprises a stabilizer. The invention further discloses a stable pharmaceutically-acceptable reconstruction liquid after tigecycline lyophilizing. The tigecycline composition has good reconstituting property, and can be dissolved without vigorous shaking, such that foams produced due to vigorous shaking can be avoided. According to the tigecycline composition for inection, and the reconstruction liquid after tigecycline composition dilution, experiment results show that oxidative degradation and epimer generation are significantly reduced, and tigecycline preparation stability is enhanced. Compared with the existing clinically used composition, the composition of the present invention has the following effects that: treatment effects of tigecycline can be increased, potential safety hazards caused by lactose can be avoided, stability during production, storage and clinical use processes is easily achieved, and clinical use requirements can be met. |
| priorityDate | 2012-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 78.